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A B S T R A C T
Background
Cough is often distressing for patients with pneumonia. Accordingly they often use over-the-counter (OTC) cough medications
(mucolytics or cough suppressants). These might provide relief in reducing cough severity, but suppression of the cough mechanism
might impede airway clearance and cause harm.
Objectives
To evaluate the efficacy of OTC cough medications as an adjunct to antibiotics in children and adults with pneumonia.
Search methods
We searched CENTRAL 2013, Issue 12, MEDLINE (January 1966 to January week 2, 2014), OLDMEDLINE (1950 to 1965),
EMBASE (1980 to January 2014), CINAHL (2009 to January 2014), LILACS (2009 to January 2014) and Web of Science (2009 to
January 2014).
Selection criteria
Randomised controlled trials (RCTs) in children and adults comparing any type of OTC cough medication with placebo, or control
medication, with cough as an outcome and where the cough is secondary to acute pneumonia.
Data collection and analysis
We independently selected trials for inclusion. We extracted data from these studies, assessed them for methodological quality without
disagreement and analyzed them using standard methods.
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Main results
There are no new trials to include in this review update. Previously, four studies with a total of 224 participants were included; one was
performed exclusively in children and three in adolescents or adults. One using an antitussive had no extractable pneumonia-specific
data. Three different mucolytics (bromhexine, ambroxol, neltenexine) were used in the remaining studies, of which only two had
extractable data. They demonstrated no significant difference for the primary outcome of ’not cured or not improved’ for mucolytics. A
secondary outcome of ’not cured’ was reduced (odds ratio (OR) for children 0.36, 95% confidence interval (CI) 0.16 to 0.77; number
needed to treat to benefit (NNTB) at day 10 = 5 (95% CI 3 to 16) and OR 0.32 for adults (95% CI 0.13 to 0.75); NNTB at day
10 = 5 (95% CI 3 to 19)). In a post hoc analysis combining data for children and adults, again there was no difference in the primary
outcome of ’not cured or not improved’ (OR 0.85, 95% CI 0.40 to 1.80) although mucolytics reduced the secondary outcome ’not
cured’ (OR 0.34, 95% CI 0.19 to 0.60; NNTB 4, 95% CI 3 to 8). The risk of bias was low or unclear.
Authors’ conclusions
There is insufficient evidence to decide whetherOTCmedications for cough associated with acute pneumonia are beneficial. Mucolytics
may be beneficial but there is insufficient evidence to recommend them as an adjunctive treatment for acute pneumonia. This leaves
only theoretical recommendations that OTCmedications containing codeine and antihistamines should not be used in young children.
P L A I N L A N G U A G E S U M M A R Y
Over-the-counter medications to help reduce cough for children and adults on antibiotics for acute pneumonia
There are many causes of acute cough, one of which is pneumonia. Cough is burdensome and impairs quality of life. Over-the-counter
(OTC) medications are commonly purchased and used by patients, and are recommended by healthcare staff as additional medications
in the treatment of pneumonia. There are many classes of OTCmedications for cough, such as mucolytics (medications that can reduce
the thickness of mucus) and antitussives (medications that suppress cough). This review aims to balance the possible benefits of these
agents with their potential risks.
In this review we found four studies with a total of 224 participants that were suitable for inclusion; one was performed exclusively
in children and three in adolescents or adults. However, data could only be obtained from two studies; both studies used mucolytics
(ambroxol and bromhexine) in conjunction with antibiotics. Combining these two studies, the rate of cure or improvement in cough
of people who received mucolytics was similar to those who did not. However, in the secondary analysis, children who received a
mucolytic were more likely to be cured of cough (the number needed to treat to benefit (NNTB) at day 10 was 5 for children and 4
for adults). There were no reported increased adverse events in the treatment group.
The range of possible adverse events associated with OTC medications for cough is wide and includes minimal adverse events (such
as with the use of honey) to serious adverse events, such as altered heart rate patterns, drowsiness and death in young children. The
studies included in this review did not report any detectable increase in adverse events. There were no obvious biases in the studies.
This review has substantial limitations due to the unavailability of data from studies. Also there are no studies of other common OTC
medications used for cough, such as antihistamines and antitussives.
Thus, there is insufficient evidence to draw any definitive conclusions on the role of OTCmedications taken as an additional treatment
for cough associated with acute pneumonia. Mucolytics may be beneficial but the lack of consistent evidence precludes recommending
the routine use of mucolytics as an addition in the treatment of troublesome cough associated with pneumonia in children or adults.
The evidence is current to January 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mucolytics as an adjunct to antibiotics to reduce cough in acute pneumonia in children and adults
Patient or population: children and adults with acute pneumonia
Settings: any
Intervention: mucolytics (and antibiotics)1
Comparison: antibiotics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Mucolytics
Number of people who
had not improved or had
not been cured
(follow-up: 7 to 10 days)
16 per 100 14 per 100
(7 to 26)
OR 0.85
(0.4 to 1.8)
221
(2)
⊕⊕©©
low2,5
Fewer people represents
a benefit
Cough score
Scale from: 0 (absent) to
3 (very severe)
(follow-up: 3 days)
The mean cough score in
the control groups was
1.45
The mean cough score
in the intervention groups
was
0.25 lower
(0.33 to 0.17 lower)
120
(1)
⊕⊕©©
low2,3,4
Data for children only
Adverse events
(follow-up: 10 days)
See comment See comment Not estimable 120
(1)
See comment 1 study in children pro-
vided data specific to par-
ticipants with pneumonia
- there were no adverse
events
Complications (e.g.
medication change)
See comment See comment Not estimable 0
(0)
See comment Complications were not
measured in the trials
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1In addition to antibiotics, people with pneumonia often use over-the-counter (OTC) cough medications when at home or request
OTC cough medications when in hospital to suppress an annoying cough. There is a question as to whether suppressing cough
may prolong pneumonia. Over-the-counter cough medications can include antitussives, expectorants, antihistamine-decongestants,
antihistamines and mucolytics (such as bromhexine, ambroxol and neltenexine).
2Allocation concealment unclear.
3Scale not validated.
4Sparse data.
5Sparse data; confidence interval does not rule out the potential for ’more people’ not improved or cured with mucolytics.
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B A C K G R O U N D
Description of the condition
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002; Cherry 2003). Acute cough (duration less
than two weeks) (Chang 2006) has multiple causes, including
pneumonia. Whatever the cause, attempting to reduce the impact
of the symptom of cough is reflected in the billions spent on over-
the-counter (OTC) cough medications. Cough impairs quality of
life (French 2002) and causes significant anxiety to the parents
of children (Cornford 1993). Accordingly, patients with pneumo-
nia sometimes self medicate with over-the-counter (OTC) cough
medications in ambulatory settings, or ask for them in hospital.
Description of the intervention
A Cochrane review showed that antihistamine-analgesic-decon-
gestion combinations have some general benefit in adults and older
children with the common cold but not in young children (de
Sutter 2012). In the management of acute cough, in the ambu-
latory setting, a Cochrane review found no good evidence for or
against the use of OTC medications (Smith 2012). There is no
clear benefit of antihistamines (either singly or in combination) in
young children for relieving acute cough (de Sutter 2012; Smith
2012). Moreover, they are associated with potentially significant
adverse events including altered consciousness, arrhythmia and
death (Gunn 2001; Kelly 2004). None of these reviews included
patients with pneumonia (Smith 2012). There are also Cochrane
reviews on chronic non-specific cough but this is unrelated to this
review, which focuses on acute cough associated with pneumonia.
How the intervention might work
Cough is usually divided into acute or chronic according to its
duration and age group. It is defined as chronic if over eight weeks
duration in adults, and over three to four weeks in children (Chang
2005). This reflects the different conditions causing chronic cough
in different age groups. In contrast, in this review we examined
the efficacy of OTCmedication for acute cough in acute pneumo-
nia, where the pathophysiological processes (albeit poorly under-
stood) are likely to be the same in children and adults.Methods for
determining cough outcomes are similar in adults and children,
although these methods remain poorly standardised. Objective
measurements of cough include cough frequency and cough sen-
sitivity outcomes, whilst subjective measurements of cough may
broadly encompass quality-of-life and outcomes based on diaries
etc. (Birring 2006; Chang 2003).
Why it is important to do this review
Although OTC cough medications might provide some relief by
reducing the severity of the cough, they might also be harmful in
prolonging pneumonia (by suppressing the cough reflex, which
might cause retention of airway debris). Thus, a systematic review
of their benefits or harms is useful to help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of OTC medications for cough as an ad-
junct to antibiotics in children and adults with pneumonia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing any type of OTC
cough medication with a placebo (or control group) with cough
as an outcome and where cough is secondary to acute pneumonia.
We excluded quasi-randomised trials.
Types of participants
We considered studies of both children and adults with cough of
less than four weeks in duration that was related to pneumonia.
We specifically excluded studies of cough of more than four weeks
in duration and cough related to another underlying cardio-respi-
ratory condition (for example, suppurative lung disease, chronic
obstructive airway disease, asthma). However, we considered stud-
ies which included cough of mixed aetiologies if data were avail-
able for the subgroup of patients with pneumonia.
Types of interventions
RCT comparisons of any type of OTC cough medication as an
adjunct therapy to antibiotics. We did not include trials compar-
ing only two or more medications without a placebo comparison
group. We included trials that included the use of other medica-
tions or interventions if all participants had equal access to such
medications (including antibiotics) or interventions.
Types of outcome measures
We attempted to obtain data on at least one of the following
outcome measures.
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Primary outcomes
1. Proportion of participants who were not cured or not
substantially improved at follow-up (failure to improve was
measured according to the hierarchy listed below in Secondary
outcomes).
Secondary outcomes
1. Proportion of participants who were not cured at follow-up.
2. Change in quantitative differences in cough (cough
frequency, cough scores, other quantitative outcomes based on
cough diary).
3. Proportion experiencing adverse effects of the intervention
(for example, sleepiness, nausea, etc.).
4. Proportion experiencing complications (for example,
requirement for medication change, etc.).
We adopted and recorded individual trial definitions.
As it was likely that studies may have differed in their definitions
of cure and improvement, we adopted a hierarchical approach that
employed the reported outcome measures. For example, if both
an objective measure and a subjective measure of cough frequency
were reported, we were to adopt the objective measure in assessing
the efficacy of treatment. Our hierarchy of outcome measures was
as follows.
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity).
2. Symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, outcomes-based cough
diary): assessed by the patient (adult or child).
3. Symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, outcomes-based cough
diary): assessed by the parents or carers.
4. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, outcomes-based cough diary): assessed by
clinicians.
5. Fever, respiratory rate, oxygen requirement.
6. Non-clinical outcomes (chest radiology, white cell count,
C-reactive protein, erythrocyte sedimentation rate, lung function
test (spirometry)).
7. Eradication of micro-organism(s) causing the pneumonia.
Search methods for identification of studies
Electronic searches
For this update we searched theCochraneCentral Register of Con-
trolled Trials (CENTRAL) 2013, Issue 12, part of The Cochrane
Library, www.thecochranelibrary.com (accessed 22 January 2014),
which contains the Acute Respiratory Infections Group’s Spe-
cialised Register, MEDLINE (January 1966 to January week 2,
2014), OLDMEDLINE (1950 to 1965), EMBASE (1980 to Jan-
uary 2014), CINAHL (2009 to January 2014), LILACS (2009 to
January 2014) and Web of Science (2009 to January 2014).
We used the following search strategy to search MEDLINE and
CENTRAL. We adapted the search strategy for EMBASE (see
Appendix 2), CINAHL (see Appendix 3), LILACS (see Appendix
4) and Web of Science (see Appendix 5).
MEDLINE (OVID)
1 Cough/
2 cough*.tw.
3 1 or 2
4 exp Pneumonia/
5 (pneumon* or bronchopneumon*).tw.
6 4 or 5
7 3 and 6
8 exp Antitussive Agents/
9 antitussiv*.tw,nm.
10 exp Expectorants/
11 expectorant*.tw,nm.
12 exp Cholinergic Antagonists/
13 (cholinergic adj2 (blocking or antagonist*)).tw,nm.
14 (anticholinergic* or anti-cholinergic*).tw,nm.
15 exp Histamine H1 Antagonists/
16 histamine h1 antagonist*.tw,nm.
17 (antihistamin* or anti-histamin*).tw,nm.
18 mucolytic*.tw,nm.
19 exp Drug Combinations/
20 drug combination*.tw.
21 exp Nonprescription Drugs/
22 ((non prescribed or non-prescribed or nonprescribed or non
prescription* or non-prescription* or nonprescription*) adj3
(drug* or medicin* or pharmaceut* or medicat*)).tw.
23 (over-the-counter* or over the counter or otc).tw.
24 (cough* adj3 (mixture* or suppress* or medicin* or remed* or
relief* or formula* or syrup*)).tw.
25 or/8-24
26 7 and 25
There were no language or publication restrictions.
Searching other resources
We searched the trials registries ClinicalTrials.gov and WHO IC-
TRP (searched 20 January 2014). We also searched lists of refer-
ences in relevant publications.
Data collection and analysis
Selection of studies
Two review authors (CCC, ABC) independently reviewed the lit-
erature searches to identify potentially relevant trials for full review
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from the title, abstract or descriptors. We conducted searches of
bibliographies and texts to identify additional studies. The same
two review authors independently selected trials for inclusion from
the full text, using specific criteria. There was no disagreement. A
third review author (ACC) was the nominated adjudicator in case
of any disagreements.
Data extraction and management
We reviewed trials that satisfied the inclusion criteria and extracted
the following information: study setting; year of study; source of
funding; patient recruitment details (including number of eligi-
ble patients); inclusion and exclusion criteria; other symptoms;
randomisation and allocation concealment method; numbers of
participants randomised; blinding (masking) of participants, care
providers and outcome assessors; dose and type of intervention;
duration of therapy; co-interventions; numbers of patients not
followed up; reasons for withdrawals from study protocol (clini-
cal, side effects, refusal and other); details on side effects of ther-
apy and whether intention-to-treat (ITT) analyses were possible.
We extracted data on the outcomes described previously. It was
planned that further information would be requested from the
trial authors, where required.
Assessment of risk of bias in included studies
Two review authors (CCC, ABC) independently performed a po-
tential bias assessment on studies included in the previous re-
view. We described seven components of potential biases under
Assessment of reporting biases in our updated review
Measures of treatment effect
Weundertook an initial qualitative comparison of all the individu-
ally analyzed studies to determine if pooling of results (meta-anal-
ysis) was reasonable. This took into account differences in study
populations, inclusion and exclusion criteria, interventions, out-
come assessment and estimated effect size.We included the results
from studies that met the inclusion criteria and reported any of
the outcomes of interest in the subsequent meta-analyses.
We calculated individual and pooled statistics for continuous out-
comes measured on the same metrics as mean differences (MD)
and standard mean differences, as indicated, with 95% confidence
intervals (CIs). We combined data for continuous outcomes mea-
sured on different metrics, with a standardised mean difference
(SMD). We calculated individual and pooled statistics as odds ra-
tio (OR) with 95% CIs for dichotomous variables.
Unit of analysis issues
Had there been any cross-over studies, we would have calculated
mean treatment differences from raw data, extracted or imputed
and entered as fixed-effect generic inverse variance (GIV) out-
comes, to provide summary weighted differences and 95% CIs.
Only data from the first arm would have been included in a meta-
analysis where data were combined with parallel studies (Elbourne
2002).
Dealing with missing data
We planned to contact trial authors for missing data when the
studies were less than 15 years old.
Assessment of heterogeneity
We described any heterogeneity between the study results and
tested to see if it reached statistical significance using the I2 statistic
(Higgins 2003). Heterogeneity is considered significant when the
P value of the Chi2 test is < 0.10 (Higgins 2011). We would have
included the 95% CI estimate using a random-effects model had
there been concerns about statistical heterogeneity.
Assessment of reporting biases
In this updated review, in line with the new Cochrane process, we
assessed the risk of bias of each study including sequence genera-
tion, allocation concealment, blinding and reporting of outcome
data.
While there are other possible biases (such as publication bias
detected by funnel plot) as outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), these were not
included.
Data synthesis
We calculated odds ratios (ORs) using a modified ITT analysis
for dichotomous outcome variables of each individual study. This
analysis assumed that participants not available for outcome as-
sessment had not improved (and probably represented a conser-
vative estimate of effect). We calculated the summary weighted
ORs and 95% CI (fixed-effect model) using the computer pro-
gram RevMan 2012. We calculated the number needed to treat to
benefit (NNTB) from the pooled OR and its 95% CI, applied to
a specified baseline risk using an online calculator (Cates 2003).
We assumed the cough indices to be normally distributed contin-
uous variables so that the mean difference in outcomes could be
estimated (mean difference). We would have estimated the stan-
dardised mean difference if studies had reported outcomes using
different measurement scales.
Subgroup analysis and investigation of heterogeneity
We planned an a priori subgroup analysis for:
1. children (14 years and younger) versus adolescents and
adults (older than 14 years);
2. hospitalised versus ambulatory settings;
3. classes of OTC cough medications:
i) antitussives (codeine and derivatives);
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ii) expectorants;
iii) mucolytics;
iv) antihistamine-decongestant combinations;
v) antihistamines alone;
vi) other drug combinations;
vii) males versus females in adults.
Sensitivity analysis
It was planned that sensitivity analyses be carried out to assess the
impact of potentially important factors on the overall outcomes:
1. study quality;
2. study size;
3. variation in the inclusion criteria;
4. differences in the medications used in the intervention and
comparison groups;
5. differences in outcome measures;
6. analysis using a random-effects model;
7. analysis by ’treatment received’;
8. analysis by ’ITT’;
9. analysis by study design, parallel and cross-over studies.
R E S U L T S
Description of studies
Results of the search
In the first version of this review (Chang 2007), the search identi-
fied 238potentially relevant titles. After reviewing the abstracts, we
obtained 21 full-text papers, included four studies and excluded
17 papers (details are in the Characteristics of excluded studies
table). Most were non-randomised studies or performed without
a placebo. A review article was identified in this search (Ida 1997)
which described three studies of dimemorfan (a dextromethor-
phan analogue) not identified using the original search strategy.
One of these three studies was described as a placebo-controlled
trial. Unfortunately we were not able to obtain this and there
was insufficient details provided in the review article (Ida 1997).
Another review paper (Mancini 1996) described three studies, of
which one appeared to include patients with acute lower respira-
tory tract infection (specified as acute bronchitis or bronchoalve-
olitis but which may have included patients with pneumonia). We
attempted to contact the trial authors but were not able to extract
data on the subgroup of patients with pneumonia, and thus we
excluded the study from further analysis.
In the 2009 update (Chang 2010), we identified two studies (Balli
2007; Titti 2000) on erdosteine (a mucolytic agent) but these
were excluded as this is not readily accessible over the counter
(details added to the Characteristics of excluded studies table). In
the 2011 and 2013 updates, we identified 32 and 49 potential
studies respectively but none fulfilled the inclusion criteria. Of
note, a study which examined the role of zinc supplementation
(Basnet 2012) was excluded as this is not an OTC drug for cough
suppression and coughwas not an outcomemeasure (details added
to the Characteristics of excluded studies table, thus totalling to
20 excluded studies in this current update).
Included studies
Four studies were included, as described in the ’Characteristics of
included studies’ table; all were available in English.However, data
specific for pneumonia were only available in two papers (Principi
1986; Roa 1995). Authors of three papers did not respond to our
correspondence requesting for further pneumonia-specific data.
Of the included studies, one study was exclusively in children
(Principi 1986), two were exclusively in adults (Aquilina 2001;
Azzopardi 1964) and one included adolescents and adults (Roa
1995).
One study utilised an antitussive (Dimyril) (Azzopardi 1964) and
three of the studies examined the efficacy of different formulations
of mucolytics (bromhexine (Roa 1995), neltenexine (Aquilina
2001) and ambroxol (Principi 1986)). In two of these studies, the
concomitant antibiotics used were reported (Principi 1986; Roa
1995).
Two studies were multicentre studies (Principi 1986; Roa 1995),
for which the funding was unspecified. Two studies were single-
centre studies (Aquilina 2001; Azzopardi 1964). One study was a
controlled non-placebo study (Roa 1995) and the rest utilised a
randomised placebo-controlled design (Aquilina 2001; Azzopardi
1964; Principi 1986). All but one study (Azzopardi 1964) used a
parallel design.
The inclusion and exclusion criteria (that is, including the defini-
tion of pneumonia) varied between the studies; only one study was
exclusively in patients with pneumonia (Principi 1986). In Roa
1995, bacterial pneumonia was defined as the presence of recent
productive phlegm, fever or leucocytosis (> 10,000 mm3) and pul-
monary infiltrates on radiographic examination. In Principi 1986,
inclusion required either a positive blood culture for a well-defined
bacterium or a chest X-ray showing lobar or sub lobar involve-
ment together with raised inflammatory markers, erythrocyte sed-
imentation rate≥ 30 mm/h and C-reactive protein≥ 25 µg/mL.
The two smaller papers (Aquilina 2001; Azzopardi 1964) which
contributed rather fewer numbers to the analysis did not clearly
define pneumonia.
The outcomes of the studies also varied and none utilised a vali-
dated scale for cough. The larger trials were performed and pub-
lished 12 and 21 years ago, respectively, and so were not method-
ologically as robust as one would expect of current-day trials
(Principi 1986; Roa 1995). The Roa 1995 trial evaluated clini-
cal response, bacteriological response and each clinical symptom
using a visual analogue scale. Both clinical and bacteriological re-
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sponses had clearly defined definitions; they defined cure as com-
plete disappearance of pretreatment signs and symptoms, and im-
provement as an improvement on the visual analogue scale but less
than cure. Principi 1986 evaluated clinical and radiological signs
and used absolute numbers and severity scores to evaluate clinical
symptoms and signs, including cough. The Aquilina 2001 trial
used severity scores on prespecified examination days and at the
end of therapy; the investigator expressed an overall assessment of
the therapeutic efficacy. The Azzopardi 1964 trial was more obvi-
ously subjective in its evaluation.
Excluded studies
As described above, we excluded 20 trials (details are provided in
the Characteristics of excluded studies table), most on the basis of
being non-randomised, with no placebo.
Risk of bias in included studies
In previous reviews, the agreement between the review authors
for the scores was good: the weighted Kappa score for the quality
assessment scale was 0.63. In the updated 2011 version we com-
pleted a ’Risk of bias’ table (Figure 1; Figure 2). Generally, there
were no glaring biases in the included studies - the majority of
parameters were assessed as low-risk or unclear risk. There were
no high-risk biases identified. Specifically the method used for se-
quence generation and whether allocation was concealed were not
clear in all the studies. However the blinding of participants and
outcomes seemed reasonable.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
See ’Characteristics of included studies’ table.
Blinding
See ’Characteristics of included studies’ table.
Incomplete outcome data
See ’Characteristics of included studies’ table.
Selective reporting
There was limited reporting in the studies. See ’Characteristics of
included studies’ table.
Other potential sources of bias
Unclear or low-risk.
Effects of interventions
See: Summary of findings for the main comparison
In one study (Azzopardi 1964) the number of participants with
pneumonia was not specified. In the other three included studies
(Aquilina 2001; Principi 1986; Roa 1995) the total number of
randomised participants was 555, of which 224 had pneumonia.
The total number who completed the trials was 518, of which
219 had pneumonia. Given the lack of data, meta-analysis could
not be performed on any outcome when children and adults were
considered separately and, thus, sensitivity analysis was irrelevant.
Single study results and the data and analysis section are described
below.
Paediatrics - Primary outcomes
Mucolytics
Principi reported that cough disappeared more rapidly in children
treated with ambroxol than in the placebo group (Principi 1986).
However, in the data and analysis section for the primary outcome
of ’not cured or not improved’ (defined on chest X-ray), there was
no significant difference between groups (odds ratio (OR) 0.40,
95% confidence interval (CI) 0.10 to 1.62) (Analysis 1.1).
Paediatrics - Secondary outcomes
1. Proportion of participants who were not cured at follow-
up
There was also no difference between groups for the secondary
outcome of ’no improvement’ (OR 0.40, 95% CI 0.10 to 1.62)
(Analysis 1.2). However, for the secondary outcome of clinically
’not cured’ there was a significant difference between groups (de-
fined on chest X-ray), as presented in the data and analysis section,
favouring the ambroxol group. The OR was 0.36 (95% CI 0.16
to 0.77) (Analysis 1.3) and the number needed to treat to benefit
(NNTB) was 5 (95% CI 3 to 16).
2. Change in quantitative differences in cough
Principi reported a significant difference between groups, favour-
ing the ambroxol group from day three onwards (Principi 1986).
The data and analysis section for mean cough scores on days 3
and 10 is shown in Analysis 2.1 and Analysis 2.2. For day 3, the
mean difference was -0.25 (95% CI -0.33 to -0.17). For day 10,
the mean difference was -0.15 (95% CI -0.17 to -0.13).
3. Adverse effects
The trial authors reported no significant adverse events in either
group (Principi 1986).
4. Other complications and reported data
Data for other secondary outcomes were not available. There were
no studies on any other type of over-the-counter (OTC) medica-
tion for cough associated with pneumonia in children.
Adults - Primary outcomes
Mucolytics
Two studies (Aquilina 2001; Roa 1995) used a mucolytic but only
data from one study (Roa 1995) could be included in this review.
In the study using neltenexine (a mucolytic), we could not obtain
data specific for those with pneumonia (n = 3) (Aquilina 2001).
The trial authors reported no significant adverse events in any of
the groups (Aquilina 2001).
Data specifically described for pneumonia were available only for
global ’clinical response’ and this is presented in the data and
analysis section (Analysis 3). For the primary outcome of clinically
’not cured or not improved’ there was no significant difference
between groups (OR 1.21, 95% CI 0.48 to 3.04) (Analysis 3.1).
11Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adults - Secondary outcomes
1. Proportion of participants who were not cured at follow-
up
There was also no significant difference between groups for the
secondary outcome ’not improved’ (OR 1.21, 95% CI 0.48 to
3.04) (Analysis 3.2). However, like the results for children treated
with amucolytic, there was a significant difference between groups
for the secondary outcome ’not cured’ (OR 0.32, 95% CI 0.13 to
0.75), NNTB 5 (95%CI 3 to 19), favouring those on bromhexine
(Analysis 3.3).
2. Change in quantitative differences in cough
The Roa study reported that for the total group (that is, adults
with pneumonia and bronchitis) the differences between cough
frequency on days three, five and seven and baseline were signif-
icantly larger in the bromhexine group compared to the control
group (Roa 1995). Data could not be extracted.
3. Adverse effects
The authors reported a total of 11 adverse events, six in the active
treatment group and five in the control group (Roa 1995).
4. Other complications and reported data
There was also a difference between groups (favouring bromhex-
ine) for cough discomfort and ease of expectoration on days three
and five, but not on day seven, as well as sputum volume on day
three, but not on days five or seven. There was no difference be-
tween the groups for difficulty in breathing or chest pain on any
day. At final evaluation significantly more participants were ’cured’
(46%) in the bromhexine group compared to the control group
(34%) (Roa 1995). There were no studies on any other type of
OTC medication for cough.
Antitussives
The Azzopardi study on 34 adults (total number assumed based
on study design (see the Characteristics of included studies table)
included adults with pneumonia (number unknown) in addition
to other lower respiratory tract infection aetiologies (Azzopardi
1964). Data on those with pneumonia alone were not available
and are not described here.
Combined data for children and adults - Primary
outcomes
Mucolytics
In a post hoc analysis, we combined data on children and adults.
There was no significant statistical heterogeneity in any of the
outcomes (Analysis 4.1 to Analysis 4.3).
In the combined data, meta-analysis showed no significant differ-
ence between groups for the primary outcome of ’not cured or not
improved’ (OR 0.85, 95% CI 0.40 to 1.80) (Analysis 4.1).
Combined data for children and adults - Secondary
outcomes
1. Proportion of participants who were not cured at follow-
up
There was also no significant difference between groups for the
secondary outcome ’not improved’ (OR 0.80, 95% CI 0.38 to
1.67) (Analysis 4.2). However, Analysis 4.3 showed a significant
difference between groups for the outcome ’not cured’ (OR 0.34,
95% CI 0.19 to 0.60), NNTB 4 (95% CI 3 to 8), favouring those
on a mucolytic.
2. Change in quantitative differences in cough
No data could be combined for this outcome.
3. Adverse effects
There was no significant difference between the groups in the
number of people who had an adverse event (OR 1.20, 95% CI
0.34 to 4.22) (Analysis 4.4).
4. Other complications and reported data
Data for other secondary outcomes could not be combined.
Sensitivity analyses
The only appropriate sensitivity analysis that could be performed
was that for Analysis 4 (combined children and adults). Statistical
heterogeneity was absent but given the clinical heterogeneity we
used a random-effects model to re-examine the results. This re-
vealed that there was still no significant difference between groups
for Analysis 4.1 (’not cured or not improved’) but the OR was al-
tered, with a wider confidence interval (OR 0.79, 95% CI to 0.27
to 2.29). For Analysis 4.2 (’not improved’), the non-significant
difference was also unaltered but the OR changed to 0.72 (95%
CI 0.21 to 2.29). For Analysis 4.3 (’not cured’), the significant
difference between groups was also preserved and there was no
difference in the OR or 95% CI (OR 0.34, 95% CI 0.19 to 0.60),
NNTB 4 (95% CI 3 to 8), favouring those on a mucolytic.
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D I S C U S S I O N
Only a few studies have examined over-the-counter (OTC) med-
ications for cough related to pneumonia.
Summary of main results
Although four studies were included in this review, only data from
two studies could be used (Principi 1986; Roa 1995). Both of these
studies examined the efficacy of a mucolytic as an adjunct in the
management of pneumonia and used cough as the principal out-
come. For the primary outcome of ’not cured or not improved’,
there was no difference between groups when we considered chil-
dren and adults separately, or when we combined data in a post
hoc analysis. However, for one of the secondary outcomes (’not
cured’) the use of a mucolytic increased the cure rate similarly
in both children and adults (number needed to treat to benefit
(NNTB) = 5). Therefore, we cannot be confident of its efficacy.
Nevertheless, based on Analysis 2.1, if a mucolytic is tried then
the time to response (that is, the “expected timeframe to which
a significant improvement is seen” (Chang 2006)), is three days.
However, these data come from only a single study.
Overall completeness and applicability of
evidence
OTC medications for cough consist of a variety of drugs used as
sole agents or in combination. These drugs include antitussives
(such as codeine derivatives), antihistamines and non-pharmaceu-
tical medications (for example, menthol) (Eccles 2002). However,
it is also possible that non-pharmaceutical additives used (such as
sugar, alcohol) may have a therapeutic effect, such that the placebo
effect of medications for cough has been reported to be as high
as 85% (Eccles 2002). Thus, it is not surprising that although
the total sample size for the combined studies was not small (N =
224), there was no effect seen for the primary outcome. Given that
there was a significant difference between groups, further evalua-
tion of mucolytics using more robust outcomes (as outlined in the
’Implications for research’) is certainly warranted.
Although adverse eventswere uncommon in the clinical trials iden-
tified in this study, there are case reports of severe adverse events,
including severe morbidity and even death (Kelly 2004).
Quality of the evidence
The quality of the evidence is low, as shown in the ’Summary of
findings for the main comparison’.
Potential biases in the review process
This systematic review is limited to four studies (with only two
with extractable data) and in these studies only a single type of
OTC medication for cough was examined. Thus, there is a clear
lack of studies in this area. Also, the inclusion criteria andoutcomes
varied among trials.
Agreements and disagreements with other
studies or reviews
A systematic review on adjunctive therapies for community-ac-
quired pneumonia (CAP) reported “We found no clinical trials as-
sessing the effectiveness of over-the-counter preparations for cough
as an adjunct to antimicrobial treatment in patients with CAP”
(Siempos 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
With the lack of evidence, the routine use of over-the-counter
(OTC) cough medications in treating children or adults with
troublesome cough associated with pneumonia cannot be recom-
mended. Of those tested, mucolytics are the only type of OTC
medication that have been shown to be possibly efficacious. The
’time to response’ (subjective cough severity) is three days when
used as an adjunct to an appropriate antibiotic. In current practice
it is recommended that young children are not given OTC cough
medications containing codeine derivatives and antihistamines be-
cause of the known adverse events of these medications.
Implications for research
Randomised controlled trials (RCTs) of OTC medications to de-
termine their effectiveness in treating cough associated with pneu-
monia are clearly needed. Current guidelines advocate that stud-
ies of antitussives should take place in patients with a clearly de-
fined clinical entity, such as pneumonia. Trials should be parallel
studies and double-blinded, given the known problems in study-
ing cough, specifically the large placebo and time period effects.
Clinical, radiological and bacteriological responses should be ob-
jectively evaluated. Based on the above data, a short trial of seven
days would suffice. Outcome measures for the clinical studies on
cough should be clearly defined using validated subjective data
and supported by objective data, if possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aquilina 2001
Methods Single-centre, double-blind, parallel, placebo-controlled RCT. Method of recruitment
was not specified
Concomitant antitussives, mucolytics and beta-2 agonist disallowed. Clinical evaluation
performed on baseline, days 3, 7 and final. Participants assessed for signs and symptoms
relevant to diagnosis of acute or chronic lung disease including sputum volume and
characteristics, dyspnoea, cough, pulmonary auscultation, difficulty in expectorating
Compliance not mentioned. Inclusion and exclusion criteria described in next column
Description of withdrawals or drop-outs not mentioned
Participants 14 participants allocated to neltenexine, 14 to placebo. 3 within group had pneumonia
but data specific to pneumonia were unavailable
Mean age of total group was 57.5 years (SD 3.04)
Inclusion criteria: adults (aged > 18 years) with acute and chronic lung disease
Exclusion criteria: pulmonary tuberculosis, lung cancer, allergy to neltenexine, severe
bronchospasm (requiring beta-2 agonist, corticosteroids or aminophylline), or pregnant
or lactating women
Interventions Neltenexine (a mucolytic), 37.4 mg tds or placebo (1 tablet tds) for 10 to 12 days
Outcomes Overall physicians’ assessment of efficacy scored: excellent, good, moderate, not satisfac-
tory. Exact quantification unspecified
Sputum volume, sputum characteristics (1 = serous to 5 = very purulent), and 5-point
scores for dyspnoea, cough, pulmonary auscultation, difficulty in expectorating, from 0
(absent) to 4 very severe
Notes Wrote to authors with no response
Data for pneumonia alone not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo used
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Aquilina 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-outs unclear
Selective reporting (reporting bias) Unclear risk Data for pneumonia alone could not be ex-
tracted
Other bias Unclear risk Data for pneumonia alone could not be ex-
tracted. Single-centre study; further infor-
mation sought from trial authors with no
response
Azzopardi 1964
Methods Single-centre, double-blind, placebo-controlled RCT. Participants recruited from inpa-
tients in the geriatric unit of Barnet GeneralHospital, England. Themethod of randomi-
sation and allocation was not described. When the medication (active or placebo) was
considered ineffective, the pharmacist was asked to change to alternate treatment. Data
card and observation record prepared for each participant, other medications recorded
and authors indicated that these factors were taken into account when assessing response
to trial drugs (but did not specify how). Inclusion and exclusion criteria not described.
Description of withdrawals or drop-outs not mentioned
Participants Total randomised unknown. Total described in group unclear as some participants could
have been counted twice given potential cross-over methodology. If assumed cross-over
was undertaken for all, total randomised would be 34
Age of participants not given
Participants had variety of aetiological factors for cough (pneumonia, acute and chronic
bronchitis, bronchiectasis, carcinoma, cardiac failure, cor pulmonale, nervous cough,
coryza, influenza)
Inclusion and exclusion criteria not described
Interventions Dimyril (active ingredient = isoaminile citrate, a codeine derivative) or placebo in identi-
cal bottles. Dose used varied. Initially 3 to 4 times/day followed by ’as necessary’ dosing
of up to 5 times a day (1 to 2 G)
Outcomes Outcomes not clearly specified
Paper stated: “The evidence of the patient, the several observers (day and night nurses,
physician, and medico-social worker), the number of doses per 24 hours, and (when
recorded) the actual cough frequencies were considered in deciding whether or not the
nuisance and frequency of cough had been reduced”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Azzopardi 1964 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not specified
Allocation concealment (selection bias) Unclear risk Method not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo used and pharmacists not con-
nected to trial involved
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo used and pharmacists not con-
nected to trial involved
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome of drop-outs and withdrawals
unclear
Selective reporting (reporting bias) Unclear risk Outcomes not clearly specified
Other bias Unclear risk Insufficient data to be certain
Principi 1986
Methods Multi-centre, double-blind, parallel, placebo-controlled RCT. Children recruited from
3 hospitals in Italy
Potential participants admitted into hospital for symptoms of pneumonia screened for
inclusion criteria (next row) Double-blinded study and all participants were treated as
inpatients and re-evaluated daily for heart rate, respiratory rate and maximal rectal body
temperature. Cough, dyspnoea and chest pathological scores also recorded daily. Chest
X-ray on admission and end of treatment. Compliance not mentioned but presumed
excellent given inpatient study
All children given antibiotics (see column on intervention). Other co-treatment (e.g.
anti-pyretic agents) not mentioned
Inclusion and exclusion criteria described in next column
Description of withdrawals or drop-outs not mentioned. As children were inpatients,
assumed most followed up. Chest X-ray follow-up rate 115/120 = 95.8%
Participants Total of 120 children randomised - 60 in each arm. Outcome measure available for 115
children (57 active arm, 58 controls), 95.8%
Antibiotic with ambroxol group: mean age not given, 11 aged < 1 year, 9 aged 1 to 2
years, 19 aged 2 to 5 years, 21 aged 5 to 12 years
Gender: M 28; F 32
Mean body weight: 17.1 kg (SD 1.08)
Antibiotic with placebo: mean age not given, 12 children aged < 1 year, 11 aged 1 to 2
years, 20 aged 2 to 5 years, 17 aged 5 to 12 years
Gender: M 38; F 22
Mean body weight 16.2 kg (SD 1.06)
Inclusion criteria: children admitted into hospital for pneumonia. Have had blood cul-
ture performed before commencement of antibiotics and positive for well-defined bac-
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Principi 1986 (Continued)
terium or a chest X-ray showing lobar and sub lobar involvement, with erythrocyte sed-
imentation rate ≥ 30 mm/h and C-reactive protein ≥ 25 µg/mL
Exclusion criteria: taken antibiotics,mucolytics ormucoregulatory drugs in the preceding
week
Interventions Trial medications consisted of ambroxol (1.5 to 2 mg/kg/day in 2 divided doses) or
placebo for 10 days. All children also given antibiotics, chosen on basis of microbiological
data or in accordance with literature on most probable aetiology for each age, for 7 to
10 days. Children aged < 5 years given oral amoxicillin or intramuscular ampicillin (50
mg/kg in 3 to 4 divided doses). Older children had oral erythromycin ethylsuccinate (50
mg/kg/day in 4 doses)
Outcomes Cough, dyspnoea and chest pathological signs scored, ranging from 0 (absent) to 3 (very
severe). Chest X-ray findings at the end of treatment were compared to pre-treatment
chest X-ray and expressed as normalised, improved or unchanged
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not specified
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs and withdrawals described
Selective reporting (reporting bias) Low risk Follow-up of > 90% of participants
Other bias Unclear risk Insufficient data to be certain
20Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roa 1995
Methods Multi-centre, double-blind, parallel RCT comparing amoxicillin plus bromhexine ver-
sus amoxycillin alone. Participants recruited from 22 centres involving internalists or
pulmonologists in the Philippines
Potential participants evaluated for inclusion criteria by history, examination, CXR,
laboratory tests (blood counts, sputum). The method of randomisation and allocation
was not described. Double-blinded study and all participants were treated as outpatients
and re-evaluated on days 3, 5, 7 and 10. Compliance monitored by pill counting
Participants allowed to receive medications for fever and constitutional symptoms but
not any other cough expectorants or antimicrobials. Inclusion and exclusion criteria
described in next column
Description of withdrawals or drop-outs mentioned for entire group. Maximum follow-
up rate 375/407 = 92% but less for other aspects
Participants Total of 407 participants randomised - 201 in active treatment and 206 in control group.
392 completed study (192 active, 200 controls). Compliance of 80% in active group
and 85% in control group
Amoxicillin with bromhexine group: mean age 32 (SD 13) years, gender - 117 M: 75 F;
51 with pneumonia, 141 with bronchitis
Amoxicillin alone: mean age 32 (SD 12), gender - 130 M: 70 F; 50 with pneumonia,
150 with bronchitis
Inclusion criteria: adolescents and adults aged 15 to 60 years with uncomplicated com-
munity-acquired lower respiratory tract infection (pneumonia or bronchitis), clinically
assessed to be bacterial in aetiology. Pneumonia defined as presence of cough < 2 weeks,
purulent phlegm, fever and/or leucocytosis (> 10,000 mm3) and pulmonary infiltrates
on CXR. Acute bronchitis defined as presence of cough < 2 weeks, purulent phlegm,
fever and/or leucocytosis (> 10,000 mm3). Sputum culture had to be sensitive to amoxi-
cillin or if organism resistant, participant included if clinical response at Day 3 occurred
on amoxicillin
Exclusion criteria: frank respiratory failure, coexistent chronic disease (diabetes, renal
failure, liver or renal impairment, terminal illness such as cancer, active tuberculosis,
healed tuberculosiswith bronchiectasis, chronic bronchitis or emphysema, heavy smokers
(undefined)), pregnant or lactating, hypersensitivity to study drugs, or recent (< 2 weeks)
treatment with antibiotics
Interventions Active Rx = amoxicillin 240 mg and bromhexine 8 mg, both 4 times/day for 7 days
Control group: amoxicillin alone, 250 mg 4 times/day for 7 days
Outcomes Days 3, 5, 7 and 10. Participants evaluated for clinical response, bacteriological response,
subjective symptom scores, adverse events, compliance, complete blood count
Clinical response:
Cured = complete disappearance of pre-treatment symptoms and signs
Improvement = pre-treatment symptoms and signs improved but not cured
Failure = pre-treatment symptoms and signs did not improve or worsened
Indeterminate = clinical response could not be determined
Clinical symptoms:
10 mm visual analogue scale of symptoms of cough frequency, cough discomfort, diffi-
culty breathing not related to cough, chest pain not related to cough, ease of expectora-
tion
Bacteriologic response:
Eradication = absence of pre-treatment pathogen or no more culturable material could
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Roa 1995 (Continued)
be expectorated
Persistence = presence of pre-treatment pathogen
Super-infection = appearance of resistant pathogen after starting treatment
Indeterminate = bacteriologic response could not be reliably assessed
Notes Wrote to authors with no response
Data for pneumonia alone available only for global clinical response outcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Data not provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up in > 90% for some outcomes but
less in others
Selective reporting (reporting bias) Low risk Outcomes of withdrawals and drop-outs
mentioned
Other bias Low risk Insufficient data to be certain but multi-
centre study from 22 centres, thus likely
low
CXR: chest X-ray
F: female
M: male
RCT: randomised controlled trial
SD: standard deviation
tds: three times a day
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aliprandi 2004 Non-placebo trial. Study involves comparing levodropropizine, codeine and cloperastine to levocloperastine
Balli 2007 Erdosteine is not legally available as an over-the-counter medication in countries such as Australia, the UK and
USA. Study compared amoxicillin plus erdosteine to amoxicillin-placebo in children with acute lower respiratory
tract infections
Barberi 1993 Non-placebo study comparing nimesulide to lysine-aspirin in children
Bartolucci 1981 Non-controlled study in 40 adults using anti-phlogistic-balsamic compound (in Italian)
Basnet 2012 RCT on zinc as adjunct treatment. No data specific to cough as an outcome measure
Caporalini 2001 Non-placebo study comparing neltenexine against N-acetylcysteine
Dotti 1970 Randomised controlled study but participants did not have pneumonia (in Italian)
Finiguerra 1981 A double-blind study in adults with acute and chronic bronchitis (not pneumonia)
Forssell 1966 Non-placebo study comparing drops to syrup formulation of an antitussive in infants and young children (in
German)
Hargrave 1975 Study examined role of bromhexine in prevention of postoperative pneumonia
Ida 1997 A review article describing 3 studies on dimemorfan, a dextromethorphan analogue. Of the 3 cited studies, one
was a placebo-controlled trial. Insufficient details were included in the text and further data were not available
from the author, who could not be contacted
Jayaram 2000 Non-placebo study comparing 2 cough formulations
Mancini 1996 The paper summarises 3 studies which were not referenced. The first of the 3 studies described a RCT in children
with “acute lower respiratory affections (e.g. acute bronchitis, bronchoalveolitis)”. Unknown if children with
pneumonia included and results stated reduction in cough scores with no specific data given. We wrote to authors
and no response was received
The other 2 studies described were in adults with ’“superinfected chronic bronchitis” and “hypersecretory chronic
obstructive bronchopneumopathies”
Pelucco 1981 Non-randomised, non-placebo study in 26 adults (in Italian)
Titti 2000 Erdosteine is not legally available as an over-the-counter medication in countries such as Australia, the UK and
USA. Multi-centre RCT compared ampicillin plus erdosteine to ampicillin-placebo in children with acute lower
respiratory tract infections
Turrisi 1984 Non-randomised, non-placebo study using fenspiride in 20 adults (in Italian)
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(Continued)
Wang 2005 Study used Fuxiong plaster (i.e. not an OTC medication). Randomised controlled study in children with pneu-
monia
Wieser 1973 Placebo but non-randomised study comparing placebo to prenodiazine in 84 adults (in German)
Zhang 2005 Study used Toubiao Qingfei (an externally applied therapy, i.e. not an OTC medication). Randomised controlled
study in children with fever from pneumonia
Zurcher 1966 Non-placebo, double-blind study comparing Sinecod-Hommel to a codeine-based antitussive in 95 adults (in
German)
OTC: over-the-counter
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Children - global assessment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Not cured or not improved 1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.10, 1.62]
2 Not improved 1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.10, 1.62]
3 Not cured 1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.16, 0.77]
Comparison 2. Children - secondary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean cough score at day 3 1 120 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.33, -0.17]
2 Mean score at day 10 1 120 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.17, -0.13]
3 Adverse events (no. of people) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Adults - global assessment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Not cured or not improved 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.48, 3.04]
2 Not improved 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.48, 3.04]
3 Not cured 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.75]
Comparison 4. Combined children and adults
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Not cured or not improved 2 221 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.40, 1.80]
2 Not improved 2 221 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.38, 1.67]
3 Not cured 2 221 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.19, 0.60]
4 Adverse events (no. of people) 2 221 Odds Ratio (M-H, Fixed, 95% CI) 1.2 [0.34, 4.22]
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Analysis 1.1. Comparison 1 Children - global assessment, Outcome 1 Not cured or not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 1 Children - global assessment
Outcome: 1 Not cured or not improved
Study or subgroup
Mucolytic
(Am-
broxol) Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 3/60 7/60 100.0 % 0.40 [ 0.10, 1.62 ]
Total (95% CI) 60 60 100.0 % 0.40 [ 0.10, 1.62 ]
Total events: 3 (Mucolytic (Ambroxol)), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytic Favours placebo
Analysis 1.2. Comparison 1 Children - global assessment, Outcome 2 Not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 1 Children - global assessment
Outcome: 2 Not improved
Study or subgroup Mucolytic (ambroxol) Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 3/60 7/60 100.0 % 0.40 [ 0.10, 1.62 ]
Total (95% CI) 60 60 100.0 % 0.40 [ 0.10, 1.62 ]
Total events: 3 (Mucolytic (ambroxol)), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytic Favours placebo
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Analysis 1.3. Comparison 1 Children - global assessment, Outcome 3 Not cured.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 1 Children - global assessment
Outcome: 3 Not cured
Study or subgroup Mucolytic (ambroxol) Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 15/60 29/60 100.0 % 0.36 [ 0.16, 0.77 ]
Total (95% CI) 60 60 100.0 % 0.36 [ 0.16, 0.77 ]
Total events: 15 (Mucolytic (ambroxol)), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytic Favours placebo
Analysis 2.1. Comparison 2 Children - secondary outcomes, Outcome 1 Mean cough score at day 3.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 2 Children - secondary outcomes
Outcome: 1 Mean cough score at day 3
Study or subgroup Mucolytic (ambroxol) Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Principi 1986 60 1.2 (0.2) 60 1.45 (0.25) 100.0 % -0.25 [ -0.33, -0.17 ]
Total (95% CI) 60 60 100.0 % -0.25 [ -0.33, -0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.05 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours mucolytic Favours placebo
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Analysis 2.2. Comparison 2 Children - secondary outcomes, Outcome 2 Mean score at day 10.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 2 Children - secondary outcomes
Outcome: 2 Mean score at day 10
Study or subgroup Mucolytic (ambroxol) Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Principi 1986 60 0.1 (0.05) 60 0.25 (0.05) 100.0 % -0.15 [ -0.17, -0.13 ]
Total (95% CI) 60 60 100.0 % -0.15 [ -0.17, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.43 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours mucolytic Favours placebo
Analysis 2.3. Comparison 2 Children - secondary outcomes, Outcome 3 Adverse events (no. of people).
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 2 Children - secondary outcomes
Outcome: 3 Adverse events (no. of people)
Study or subgroup Mucolytic (ambroxol) Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 0/60 0/60 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Mucolytic (ambroxol)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours mucolytic Favours placebo
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Analysis 3.1. Comparison 3 Adults - global assessment, Outcome 1 Not cured or not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 3 Adults - global assessment
Outcome: 1 Not cured or not improved
Study or subgroup Mucolytic - bromhexi Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roa 1995 13/51 11/50 100.0 % 1.21 [ 0.48, 3.04 ]
Total (95% CI) 51 50 100.0 % 1.21 [ 0.48, 3.04 ]
Total events: 13 (Mucolytic - bromhexi), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytic Favours placebo
Analysis 3.2. Comparison 3 Adults - global assessment, Outcome 2 Not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 3 Adults - global assessment
Outcome: 2 Not improved
Study or subgroup Mucolytic - bromhexi Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roa 1995 13/51 11/50 100.0 % 1.21 [ 0.48, 3.04 ]
Total (95% CI) 51 50 100.0 % 1.21 [ 0.48, 3.04 ]
Total events: 13 (Mucolytic - bromhexi), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytic Favours placebo
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Analysis 3.3. Comparison 3 Adults - global assessment, Outcome 3 Not cured.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 3 Adults - global assessment
Outcome: 3 Not cured
Study or subgroup Mucolytics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roa 1995 27/51 39/50 100.0 % 0.32 [ 0.13, 0.75 ]
Total (95% CI) 51 50 100.0 % 0.32 [ 0.13, 0.75 ]
Total events: 27 (Mucolytics), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours mucolytics Favours placebo
Analysis 4.1. Comparison 4 Combined children and adults, Outcome 1 Not cured or not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 4 Combined children and adults
Outcome: 1 Not cured or not improved
Study or subgroup Mucolytic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 3/60 7/60 44.5 % 0.40 [ 0.10, 1.62 ]
Roa 1995 13/51 11/50 55.5 % 1.21 [ 0.48, 3.04 ]
Total (95% CI) 111 110 100.0 % 0.85 [ 0.40, 1.80 ]
Total events: 16 (Mucolytic), 18 (Placebo)
Heterogeneity: Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours mucolytic Favours placebo
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Analysis 4.2. Comparison 4 Combined children and adults, Outcome 2 Not improved.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 4 Combined children and adults
Outcome: 2 Not improved
Study or subgroup Mucolytic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 3/60 8/60 47.9 % 0.34 [ 0.09, 1.36 ]
Roa 1995 13/51 11/50 52.1 % 1.21 [ 0.48, 3.04 ]
Total (95% CI) 111 110 100.0 % 0.80 [ 0.38, 1.67 ]
Total events: 16 (Mucolytic), 19 (Placebo)
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mucolytic Favours placebo
Analysis 4.3. Comparison 4 Combined children and adults, Outcome 3 Not cured.
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 4 Combined children and adults
Outcome: 3 Not cured
Study or subgroup Mucolytic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 15/60 29/60 54.0 % 0.36 [ 0.16, 0.77 ]
Roa 1995 27/51 39/50 46.0 % 0.32 [ 0.13, 0.75 ]
Total (95% CI) 111 110 100.0 % 0.34 [ 0.19, 0.60 ]
Total events: 42 (Mucolytic), 68 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00023)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours mucolytic Favours placebo
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Analysis 4.4. Comparison 4 Combined children and adults, Outcome 4 Adverse events (no. of people).
Review: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
Comparison: 4 Combined children and adults
Outcome: 4 Adverse events (no. of people)
Study or subgroup Mucolytic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Principi 1986 0/60 0/60 Not estimable
Roa 1995 6/51 5/50 100.0 % 1.20 [ 0.34, 4.22 ]
Total (95% CI) 111 110 100.0 % 1.20 [ 0.34, 4.22 ]
Total events: 6 (Mucolytic), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours mucolytic Favours placebo
A P P E N D I C E S
Appendix 1. Previous search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 2) which contains the
Acute Respiratory Infections Group’s Specialised Register; MEDLINE (January 1966 to July Week 1, 2009); OLDMEDLINE (1950
to 1965); EMBASE (1980 to July 2009).
The following search strategy was run in MEDLINE and CENTRAL and adapted for EMBASE.
MEDLINE (OVID)
1 exp Cough/
2 cough.mp.
3 or/1-2
4 exp Pneumonia/
5 pneumonia.mp.
6 or/4-5
7 exp Antitussive Agents/
8 antitussive agent$.mp.
9 exp Expectorants/
10 expectorant$.mp.
11 exp Cholinergic Antagonists/
12 cholinergic antagonist$.mp.
13 exp Histamine H1 Antagonists/
14 histamine H1 antagonist$.mp.
15 mucolytic$.mp.
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16 exp Drug Combinations/
17 drug combination$.mp.
18 exp Drugs, Non-Prescription/
19 non prescription drug$.mp.
20 (over-the-counter or over the counter or OTC).mp.
21 or/7-20
22 3 and 6 and 21
EMBASE.com search strategy
1. ’coughing’/exp
2. cough*:ti,ab
3. #1 OR #2
4. ’pneumonia’/exp
5. pneumon*:ti,ab
6. #4 OR #5
7. ’antitussive agent’/exp
8. antitussiv*:ti,ab
9. ’expectorant agent’/exp
10. expectorant*:ti,ab
11. ’cholinergic receptor blocking agent’/exp
12. ’cholinergic antagonist’:ti,ab OR ’cholinergic antagonists’:ti,ab
13. ’histamine h1 receptor antagonist’/exp
14. ’histamine h1 antagonist’:ti,ab OR ’histamine h1 antagonists’:ti,ab
15. ’mucolytic agent’/exp
16. mucolytic*:ti,ab
17. ’drug combination’/exp
18. ’drug combination’:ti,ab OR ’drug combinations’:ti,ab
19. ’non prescription drug’/exp
20. ’non prescription drug’:ti,ab OR ’non prescription drugs’:ti,ab OR ’non-prescription drug’:ti,ab OR
’non-prescription drugs’:ti,ab
21. ’over the counter’:ti,ab OR ’over-the-counter’:ti,ab OR otc:ti,ab
22. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
23. #3 AND #6 AND #22
There were no language or publication restrictions.
Appendix 2. Embase.com search strategy
#31. #27 AND #30
#30. #28 OR #29
#29. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti
#28. ’randomized controlled trial’/expOR ’single blind procedure’/exp OR ’double blind procedure’/expOR ’crossover procedure’/exp
#27. #7 AND #26
#26. #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
OR #23 OR #24 OR #25
#25. (cough* NEAR/3 (suppress* OR mixture* OR syrup* OR medicine* OR remed* OR relief* OR formula*)):ab,ti
#24. ’over-the-counter’:ab,ti OR ’over the counter’:ab,ti OR otc:ab,ti
#23. ((’non presciption’ OR ’non prescribed’) NEAR/3 (drugs* OR medicine* OR medicat* OR pharmaceut*)):ab,ti
#22. ((nonprescribed OR nonprescription) NEAR/3 (drug* OR medicine* OR pharmaceut* OR medicat*)):ab,ti
#21. ’non prescription drug’/de
#20. (drug* NEAR/2 combination*):ab,ti
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#19. ’drug combination’/exp
#18. mucolytic*:ab,ti
#17. ’mucolytic agent’/exp
#16. antihistamin*:ab,ti OR ’anti-histamine’:ab,ti OR ’anti-histamines’:ab,ti OR ’histamine h1antagonist’:ab,ti OR ’histamine
h1antagonists’:ab,ti
#15. ’histamine h1 receptor antagonist’/exp
#14. anticholinergic*:ab,ti OR ’anti-cholinergic’:ab,ti OR ’anti-cholinergics’:ab,ti
#13. (cholinergic NEAR/2 (blocking OR antagonist*)):ab,ti
#12. ’cholinergic receptor blocking agent’/exp
#11. expectorant*:ab,ti
#10. ’expectorant agent’/exp
#9. antitussiv*:ab,ti
#8. ’antitussive agent’/de
#7. #3 AND #6
#6. #4 OR #5
#5. pneumon*:ab,ti OR bronchopneumon*:ab,ti
#4. ’pneumonia’/exp
#3. #1 OR #2
#2. cough*:ab,ti
#1. ’coughing’/de OR ’irritative coughing’/de
Appendix 3. CINAHL (Ebsco) search strategy
S27 S7 AND S26
S26 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR
S23 OR S24 OR S25
S25 TI (cough* W1 (mixtur* or medicin* or suppress* or relief* or remed* or formul* or syrup*)) OR AB (cough* W1 (mixtur* or
medicin* or suppress* or relief* or remed* or formul* or syrup*))
S24 TI (over the counter or over-the-counter or otc) OR AB (over the counter or over-the-counter or otc)
S23 TI (nonprescribed drug* or non-prescribed drug* or nonprescribed medicin* or non-prescribed medicin* or nonprescribed phar-
maceut* or non-prescribed pharmaceut* or nonprescribed medicat* or non-prescribed medicat*) OR AB (nonprescribed drug* or non-
prescribed drug* or nonprescribed medicin* or non-prescribed medicin* or nonprescribed pharmaceut* or non-prescribed pharmaceut*
or nonprescribed medicat* or non-prescribed medicat*)
S22TI (nonprescription drug* or non-prescription drug* or nonprescription medicin* or non-prescription medicin* or nonprescription
pharmaceut* or non-prescription pharmaceut* or nonprescription medicat* or non-prescription medicat*) OR AB (nonprescription
drug* or non-prescription drug* or nonprescription medicin* or non-prescription medicin* or nonprescription pharmaceut* or non-
prescription pharmaceut* or nonprescription medicat* or non-prescription medicat*)
S21 (MH “Drugs, Non-Prescription”)
S20 TI drug* N2 combination* OR AB drug* N2 combination*
S19 (MH “Drug Combinations+”)
S18 TI mucolytic* OR AB mucolytic*
S17 TI histamin* h1 antagonist* OR AB histamin* h1 antagonist* 37
S16 TI (antihistamin* or anti-histamin*) OR AB (antihistamin* or anti-histamin*)
S15 (MH “Histamine H1 Antagonists+”)
S14 TI (anticholinergic* or anti-cholinergic*) OR AB (anticholinergic* or anti-cholinergic*)
S13 TI (cholinergic N2 (antagonist* or blocking)) OR AB (cholinergic N2 (antagonist* or blocking))
S12 (MH “Cholinergic Antagonists+”)
S11 TI expectorant* OR AB expectorant*
S10 (MH “Expectorants+”)
S9 TI antitussiv* OR AB antitussiv*
S8 (MH “Antitussive Agents+”)
S7 S3 AND S6
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S6 S4 OR S5
S5 TI (pneumon* or bronchopneumon*) OR AB (pneumon* or bronchopneumon*)
S4 (MH “Pneumonia+”)
S3 S1 OR S2
S2 TI cough* OR AB cough*
S1 (MH “Cough”)
Appendix 4. LILACS (BRIEME) search strategy
((mh:“Antitussive Agents” OR antitusígenos OR antitussígenos OR antitusivos OR “Agentes Béquicos” OR “Substâncias Béquicas” OR
“Medicamentos Béquicos” OR antituss* ORmh:expectorants OR expectorantes ORmucolytic* ORmucolíticos OR expectorante OR
expectorant*ORmh:“Cholinergic Antagonists”OR “Acetylcholine Antagonists”OR “Anticholinergic Agents”OR “Cholinergic-Block-
ing Agents” OR cholinolytics OR “Antagonistas Colinérgicos” OR “Antagonistas de la Acetilcolina” OR “Agentes Anticolinérgicos” OR
“Agentes Bloqueadores Colinérgicos” OR colinolíticos OR mh:d27.505.519.625.120.200* OR mh:d27.505.696.577.120.200* OR
anticholinergic* OR “anti-cholinergic” OR “anti-cholinergics” ORmh:“Histamine H1 Antagonists” OR “Histamine H1 Receptor An-
tagonists” OR “Histamine H1Receptor Blockaders” ORmh:d27.505.519.625.375.425.400* ORmh:d27.505.696.577.375.425.400*
OR “Antagonistas de los Receptores Histamínicos H1” OR “Antihistamínicos Clásicos” OR “Antihistamínicos H1” OR “Antagonistas
del Receptor H1 de Histamina” OR “Bloqueadores de los Receptores Histamínicos H1” OR “Bloqueadores de los Receptores H1
de Histamina” OR “Antagonistas dos Receptores Histamínicos H1” OR “Anti-Histamínicos H1” OR “Antagonistas dos Receptores
H1 de Histamina” OR “Bloqueadores dos Receptores Histamínicos H1” OR “Bloqueadores dos Receptores H1 de Histamina” OR
mh:d26.530* OR mh:“Nonprescription Drugs” OR “Over-the-Counter” OR otc OR “over the counter” OR “Medicamentos sin
Prescripción” OR “Medicamentos de Venta Libre” OR “Medicamentos de Libre Circulación” OR “Medicamentos sem Prescrição” OR
“Medicamentos não Prescritos” OR “Medicamentos de Venda Livre” OR “Medicamentos de Livre Circulação” OR “Medicamentos
Isentos de Prescrição” OR mips OR “Drug Combinations” OR mh:d26.310.500* OR “Multi-Ingredient Cold Medications” OR
“Medicamentos Compuestos” OR “Medicamentos Compostos”) AND (mh:cough OR cough* OR tos*) AND (mh:pneumonia OR
mh:c08.381.677* OR mh:c08.730.610* OR pneumon* OR bronchopneumon* OR neumonía OR “Inflamación Experimental del
Pulmón” OR “Inflamación del Pulmón” OR “Neumonía Lobar” OR neumonitis OR “Inflamación Pulmonar” OR pulmonía OR
“Inflamação Experimental dos Pulmões” OR “Inflamação do Pulmão” OR “Pneumonia Lobar” OR pneumonite OR “Inflamação
Pulmonar”)) AND db:(“LILACS”)
Appendix 5. Web of Science (Thomson ISI) search strategy
# 6 44 #5 AND #1
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
# 5 28,361 #4 OR #3 OR #2
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
# 4 890 Topic=(cough* NEAR/3 (mixtur* or medicin* or suppress* or relief* or remed* or formul* or syrup*))
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
# 3 924 Topic=((nonprescription* or nonprescribed* or “non prescribed” or “non prescription” or non-prescribed or non-
prescription) NEAR/3 (drug* or medicin* or pharmaceut* or medicat*))
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
# 2 27,059 Topic=(antitussiv* or expectorant* or (cholinergic NEAR/2 (blocking or antagonist*)) or anticholinergic* or anti-
cholinergic* or “histamin* h1 antagonist*” or antihistamin* or anti-histamin* or mucolytic* or over-the-counter or
otc or “over the counter”)
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(Continued)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
# 1 2,727 Topic=(cough*) AND Topic=(pneumon* OR bronchopneumon*)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
WH A T ’ S N E W
Last assessed as up-to-date: 22 January 2014.
Date Event Description
22 January 2014 New search has been performed Searches updated. No new trials were identified for in-
clusion. We excluded one new trial (Basnet 2012) in
this update.
22 January 2014 New citation required but conclusions have not changed Our conclusions remain unchanged.
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 4, 2007
Date Event Description
8 August 2011 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
10 July 2009 New search has been performed Searches conducted. No new included studies found.
Two new studies excluded
21 February 2008 Amended ’Summary of findings’ table added.
30 January 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by Christina C Chang (CCC), Anne B Chang (ABC) and Allen C Cheng (ACC) based on previous protocols
on cough in children.
For the review: CCC and ABC selected articles from the search, performed the data extraction and data analysis, and wrote the review.
ACC was the adjudicator if disagreement occurred and contributed to writing the review.
D E C L A R A T I O N S O F I N T E R E S T
ABC: none known. CCC: none known. ACC: none known.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Anti-Bacterial Agents [∗therapeutic use]; Antitussive Agents [∗therapeutic use]; Chemotherapy, Adjuvant [methods];
Cough [∗drug therapy; etiology]; Drug Therapy, Combination [methods]; Expectorants [therapeutic use]; Nonprescription Drugs
[∗therapeutic use]; Pneumonia [complications; ∗drug therapy]; Randomized Controlled Trials as Topic; Treatment Outcome
MeSH check words
Adolescent; Adult; Child; Humans
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